Cipla's NDA for Argatroban in Sodium Chloride Receives AP Status from FDA
Cipla's supplemental NDA for Argatroban in Sodium Chloride has been granted an Approval Pending (AP) status by the FDA.
Asset / Drug
Drug and asset intelligence for Cipla with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.